TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02415387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: typhoid vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: typhoid vaccine
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IM
Study: NCT00561171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPP635
Description: oral once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPP635
Description: oral once daily
Study: NCT04355299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: received usual care
Study: NCT05583682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
Study: NCT02672540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE 320 mg/kg
Description: Two-hour infusion of SANGUINATE on Day 1 and Day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two-hour infusion of Normal Saline and Day 1 and Day 2
Study: NCT05476406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: äKwä skincare system products
Description: The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: competitor products (control)
Description: Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
Study: NCT04085393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Description: GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Description: GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
Study: NCT01984788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCX4161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00944671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine (+) calcium carbonate (+) magnesium hydroxide tablet
Description: A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water
Description: A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water
Description: A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
Study: NCT01902823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services from a Nurse Navigator
Description: Services from a Nurse Navigator
Study: NCT01282632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
Study: NCT01202851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
Study: NCT02683915

Intervention type: PROCEDURE
Intervention: Therapeutic hypothermia
Description: Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
Study: NCT04426123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Intramuscular injection with NaCl in m.masseter and m.temporalis.
Study: NCT03839147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
Study: NCT01452126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine concentration
Description: Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
Study: NCT01233947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464 + Faslodex
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
Study: NCT01516372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg
Description: 1200 mg of Gen administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gen 6000 mg
Description: 6000 mg of Gen administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn Placebo
Description: Placebo to match GEn Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn Placebo
Description: Placebo to match GEn Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo to match Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo to match Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg Moxifloxacin administered as a single dose
Study: NCT03127930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
Study: NCT04502914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open-to-air strategy
Description: In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
Study: NCT04031378

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation
Description: SBRT to a single dose of 24 Gy to up to 3 sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
Description: SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
Study: NCT04502914

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional closed-wound management
Description: In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
Study: NCT00875446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V Infusion
Study: NCT02852330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SA16 research software
Description: Software for measurement of voltage tomography intraoperatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS19 (1.6.2)
Description: Software for measurement of voltage tomography post-operatively.
Study: NCT01448642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
Study: NCT04333550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Intravenous infusion of Deferoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Intravenous infusion of Deferoxamine
Study: NCT00821106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right radial
Description: diagnostic or interventional procedures performed through right transradial approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left radial
Description: diagnostic or interventional procedures performed through left transradial approach
Study: NCT03629431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic non-invasive ventilation
Description: The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative standard care
Description: Standard care received postoperatively
Study: NCT03258931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Crenolanib will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midostaurin
Description: Midostaurin will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m² IV continuous infusion over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 100 mg/m² IV continuous infusion over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duanorubicin
Description: 90 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duanorubicin
Description: 90 mg/m2 IV
Study: NCT02678975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 400 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper
Description: nutritional supplement with copper, 2 mg daily
Study: NCT01588145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Study: NCT04183205

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: LDAEP
Description: This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
Study: NCT00718432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and nutritional integrated care
Description: Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care with education
Description: The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST) integrated care
Description: Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
Study: NCT03841409

Intervention type: OTHER
Intervention: Collection of blood samples
Description: Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
Study: NCT01675947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2%
Study: NCT02643485

Intervention type: PROCEDURE
Intervention: Forefoot surgery
Description: Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
Study: NCT01622478

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis

Intervention type: PROCEDURE
Intervention: complete axillary lymph node dissection
Description: Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy

Intervention type: PROCEDURE
Intervention: positron emission tomography and ultrasonogram
Description: Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
Study: NCT03577457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Study: NCT01202851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Testing
Description: 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Testing
Description: 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva Testing
Description: 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
Study: NCT00062062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT02678975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkylating Agents
Description: Alkylating antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkylating Agents
Description: Alkylating antineoplastic agent
Study: NCT05058235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bent leg raise
Description: Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins.
Study: NCT03681665

Intervention type: OTHER
Intervention: ultralow dose abdominopelvic CT
Description: In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
Study: NCT01705730

Intervention type: DRUG
Intervention: tocilizumab
Description: Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
Study: NCT00515489

Intervention type: DRUG
Intervention: Risperidone
Description: as prescribed
Study: NCT02027961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous dose of 3 or 10 mg/kg durvalumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous dose of 3 or 10 mg/kg durvalumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous dose of 3 or 10 mg/kg durvalumab.